Factors influencing the onset of tuberculosis in HIV-positive adults receiving highly active antiretroviral therapy in the coastal area of Kenya
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20254008Keywords:
HAART, HIV-positive people, TB developmentAbstract
Background: Tuberculosis is one of the most common infectious diseases in patients with HIVAIDS. The purpose of this study was to determine the factors that influence the development of tuberculosis in HIV-positive patients who frequent public hospitals in coastal Kenya.
Methods: A retrospective study was conducted in a hospital environment with 600 HIV-positive adults undergoing highly active antiretroviral treatment (HAART) at 35 government hospitals in Mombasa County.
Results: The patient’s age (AOR=1.120; 95% CI: 1.011-2.231), initial CD4 cell count (AOR=0.870; 95% CI: 0.710-0.940), individuals residing independently (AOR=1.200; 95% CI: 1.048-1.120), female patients undergoing treatment (AOR=0.775; 95% CI: 0.562-0.843), absence of opportunistic infections (AOR=0.862; 95% CI: 0.728-0.932), those who have not disclosed their HIV status (AOR=1.239; 95% CI: 1.081-2.339), patients living in rural areas (AOR=1.132; 95% CI: 1.030-1.451), individuals lacking formal education (AOR=1.120; 95% CI: 1.052-1.541), patients demonstrating poor adherence to treatment (AOR=1.221; 95% CI: 1.190-2.451), bedridden patients (AOR=1.222; 95% CI: 1.129-1.519), ambulatory patients (AOR=1.153; 95% CI: 1.090-1.263), and non-smokers (AOR=0.850; 95% CI: 0.681-0.932) were all significantly associated with the variable being studied.
Conclusions: Additionally, factors such as alcohol consumption, drug toxicity, and the initial clinical WHO stages significantly influenced the advancement of tuberculosis in HIV-positive individuals receiving treatment.
Metrics
References
World Health Organization. Global HIV Programme. HIV data and statistics. 2021. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics. Accessed on 15 April 2023.
WHO/AIDS key facts. 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids. Accessed on 15 April 2023.
WHO. Global Tuberculosis Report 2020. 2020. Available from: https://www.who.int/publications/ i/item/9789240013131. Accessed on 15 April 2023.
World Health Organization. Updated recommendations on first-line and second- line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Available from: https://www.who.int/publications/i/item/WHO-CDS-HIV-18.51. Accessed on 17 July 2022.
Enos M, Sitienei J, Ong’ang’o J, Mungai B, Kamene M, Wambugu J, et al. Kenya tuberculosis prevalence survey 2016: Challenges and opportunities of ending TB in Kenya. PLoS One. 2018;13(12):e0209098. DOI: https://doi.org/10.1371/journal.pone.0209098
World Health Organization. Global Tuberculosis Report 2019. 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1. Accessed on 17 June 2023.
Ahmed A, Mekonnen D, Shiferaw AM, Belayneh F, Yenit MK. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study. BMJ Open. 2018;8(2):e016961. DOI: https://doi.org/10.1136/bmjopen-2017-016961
Mohammed H, Assefa N, Mengistie B. Prevalence of extrapulmonary tuberculosis among people living with HIV/AIDS in sub-Saharan Africa: a systemic review and meta-analysis. HIV/AIDS Res Palliat Care. 2018;10:225-37. DOI: https://doi.org/10.2147/HIV.S176587
Ayalaw SG, Alene KA, Adane AA. Incidence and predictors of tuberculosis among HIV positive children at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow‐up study. Int Schol Res Notices. 2015;2015(1):307810. DOI: https://doi.org/10.1155/2015/307810
Endalamaw A, Engeda EH, Tezera N. Incidence of tuberculosis in children on antiretroviral therapy: a retrospective cohort study. BMC Res Notes. 2018;11:745. DOI: https://doi.org/10.1186/s13104-018-3846-z
Taha M, Deribew A, Tessema F, Assegid S, Duchateau L, Colebunders R. Risk factors of active tuberculosis in people living with HIV/AIDS in southwest Ethiopia: a case control study. Ethiop J Health Sci. 2011;21. DOI: https://doi.org/10.4314/ejhs.v21i2.69053
Masini EO, Mansour O, Speer CE, Addona V, Hanson CL, Sitienei JK, et al. Using survival analysis to identify risk factors for treatment interruption among new and retreatment tuberculosis patients in Kenya. PLoS One. 2016;11(10):e0164172. DOI: https://doi.org/10.1371/journal.pone.0164172
Abdullahi OA, Ngari MM, Sanga D, Katana G, Willetts A. Mortality during treatment for tuberculosis; a review of surveillance data in a rural county in Kenya. PLoS One. 2019;14(7):e0219191. DOI: https://doi.org/10.1371/journal.pone.0219191
Mecha JO, Kubo EN, Nganga LW, Muiruri PN, Njagi LN, Ilovi S, et al. Trends, treatment outcomes, and determinants for attrition among adult patients in care at a large tertiary HIV clinic in Nairobi, Kenya: a 2004-2015 retrospective cohort study. HIV AIDS. 2018;10:103-14. DOI: https://doi.org/10.2147/HIV.S153185
Pathmanathan I, Pasipamire M, Pals S, Dokubo EK, Preko P, Ao T, et al. High uptake of antiretroviral therapy among HIV-positive TB patients receiving co-located services in Swaziland. PLoS One. 2018;13(5):e0196831. DOI: https://doi.org/10.1371/journal.pone.0196831
Marum E, Taegtmeyer M, Chebet K. Scale-up of voluntary HIV counselling and testing in Kenya. JAMA. 2006;296(7):859-62. DOI: https://doi.org/10.1001/jama.296.7.859
Wekesa E. HIV testing experiences in Nairobi slums: the good, the bad and the ugly. BMC Public Health. 2019;19(1):1600. DOI: https://doi.org/10.1186/s12889-019-7975-7
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48-57. DOI: https://doi.org/10.1016/S0140-6736(08)61697-9
National AIDS and STI Control Program. Guidelines on use of antiretroviral drugs for treating and preventing HIV infections in Kenya. 2016.
World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015.
Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis. 2015;60(4):639-45. DOI: https://doi.org/10.1093/cid/ciu849
Karanja M, Kingwara L, Owiti P, Kirui E, Ngari F, Kiplimo R, et al. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: a retrospective study of routine health care data. PLoS One. 2020;15(12):e0234588. DOI: https://doi.org/10.1371/journal.pone.0234588
Abera A, Fenti B, Tesfaye T, Balcha F. Factors influencing adherence to antiretroviral therapy among people living with HIV/AIDS at ART Clinic in Jimma University teaching hospital, Southwest Ethiopia. J Pharma Rep. 2015;1(101):2.
Molla AA, Gelagay AA, Mekonnen HS, Teshome DF. Adherence to antiretroviral therapy and associated factors among HIV positive adults attending care and treatment in University of Gondar Referral Hospital, Northwest Ethiopia. BMC Infect Dis. 2018;18(1):266. DOI: https://doi.org/10.1186/s12879-018-3176-8
Gebreagziabher T, Woldemariam GT. Antiretroviral treatment adherence and determinant factors among adult people infected with human immunodeficiency virus in eastern Tigray general hospitals, northern Ethiopia, 2019. HIV/AIDS Res Palliat Care. 2020;12:497-505. DOI: https://doi.org/10.2147/HIV.S273917
Kwobah CM, Mwangi AW, Koech JK, Simiyu GN, Siika AM. Factors associated with first-line antiretroviral therapy failure amongst HIV-Infected African patients: a case-control study. World J AIDS. 2012;2:271-8. DOI: https://doi.org/10.4236/wja.2012.24036
Chakaya JM, Harries AD, Marks GB. Ending tuberculosis by 2030-Pipe dream or reality? Int J Infect Dis. 2020;92S:S51-4. DOI: https://doi.org/10.1016/j.ijid.2020.02.021
Naidoo P, Peltzer K, Louw J, Matseke G, Mchunu G, Tutshana B. Predictors of tuberculosis (TB) and antiretroviral (ARV) medication non-adherence in public primary care patients in South Africa: a cross sectional study. BMC Public Health. 2013;13(1):396. DOI: https://doi.org/10.1186/1471-2458-13-396
Rogerson SJ, Wijesinghe RS, Meshnick SR. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis. 2010;10(1):51-9. DOI: https://doi.org/10.1016/S1473-3099(09)70322-6
Yonge SA, Otieno MF, Sharma RR, Omedo RA. Risk factors in transmission of Tuberculosis in Mombasa, Kenya. A descriptive epidemiological study. Int J Trop Dis Health. 2016;13(4):1-10. DOI: https://doi.org/10.9734/IJTDH/2016/23621
Yonge SA, Otieno MF, Sharma RR, Nteka SS. Human immunodeficiency virus and immunological profiles among suspected tuberculosis cases in Mombasa County, Kenya. J Tubercul Res. 2016;4:34-45. DOI: https://doi.org/10.4236/jtr.2016.41005
Okonko IO, Ejike IU, Innocent-Adiele C, Cookey TI. HIV coinfections with tuberculosis among HIV-1 infected individuals in old Cross River State, Nigeria. J Immunoassay Immunochem. 2020;41(3):245-56. DOI: https://doi.org/10.1080/15321819.2020.1717527
Nagu TJ, Aboud S, Mwiru R, Matee MI, Rao M, Fawzi WW, et al. Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy. Int J Infect Dis. 2017;56:39-44. DOI: https://doi.org/10.1016/j.ijid.2017.01.023
Yonge SA, Otieno MF, Sharma RR, Nteka SS. Clinical manifestations and CD4 counts of tuberculosis in human immunodeficiency virus-infected and un-infected among newly diagnosed patients in Mombasa, Kenya. Int J Trop Dis Health. 2016;16(4):1-13. DOI: https://doi.org/10.9734/IJTDH/2016/25263
Koneru S, Kocharla L, Higgins GC, Ware A, Passo MH, Farhey YD, et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol. 2008;14(4):195-201. DOI: https://doi.org/10.1097/RHU.0b013e31817a242a
Gao L, Zhou F, Li X, Jin Q. HIV/TB co-infection in mainland China: a meta-analysis. PloS One. 2010;5(5):e10736. DOI: https://doi.org/10.1371/journal.pone.0010736
Fenta A, Demeke G, Bitew A, Kebede D, Hailu T. Prevalence and associated factors of TB co-morbidity among HIV sero-positive individuals in Shegaw Motta District Hospital, Ethiopia. Int J Gen Med. 2020:1529-36. DOI: https://doi.org/10.2147/IJGM.S278758
Ranganath TS, Kishore SG, Reddy R, Murthy HD, Vanitha B, Sharath BN, et al. Risk factors for non-adherence among people with HIV-associated TB in Karnataka, India: a case-control study. Indian J Tubercul. 2022;69(1):65-72. DOI: https://doi.org/10.1016/j.ijtb.2021.03.003
Wessels J. Nutritional status of patients with tuberculosis and TB/HIV co-infection at Standerton TB specialised hospital, Mpumalanga. University of the Free State. 2017.
Shankar EM, Vignesh R, Ellegård R, Barathan M, Chong YK, Bador MK, et al. HIV–Mycobacterium tuberculosis co-infection: a ‘danger-couple model’of disease pathogenesis. Path Dis. 2014;70(2):110-8. DOI: https://doi.org/10.1111/2049-632X.12108
Buck WC, Olson D, Kabue MM, Ahmed S, Nchama LK, Munthali A, et al. Risk factors for mortality in Malawian children with human immunodeficiency virus and tuberculosis co-infection. Int J Tubercul Lung Dis. 2013;17(11):1389-95. DOI: https://doi.org/10.5588/ijtld.13.0030
Bayabil S, Seyoum A. Joint modelling in detecting predictors of CD4 cell count and status of tuberculosis among people living with HIV/AIDS under HAART at Felege Hiwot teaching and specialized Hospital, North-West Ethiopia. HIV/AIDS. 2021;13:527. DOI: https://doi.org/10.2147/HIV.S307069
Downloads
Published
How to Cite
Issue
Section
